Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Clinical Report: Zentalis hold resurfaces WEE1 safety concerns

Plus data from BioNTech, MediLink, Nurix, Aerovate and more

June 19, 2024 12:53 AM UTC

A clinical hold on monotherapy studies of Zentalis’ azenosertib has sparked concerns among investors that the WEE1 inhibitor may face the same safety issues as other therapies in the class.

Shares of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) fell 51% to $4.14 on Tuesday after the company announced FDA had placed a clinical hold on three azenosertib monotherapy studies after two deaths occurred in one of them, the Phase II DENALI trial in platinum-resistant ovarian cancer. The other two studies are a Phase I dose-escalation trial and the Phase II TETON study in uterine serous carcinoma. The deaths are presumed to be due to sepsis...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article